Citations (128)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Cisio De Oliveira Brandao, Sandra Lewis, Darcie Sandschafer & Jeffrey Crawford. (2023) Two decades of pegfilgrastim: what have we learned? Where do we go from here?. Current Medical Research and Opinion 39:5, pages 707-718.
Read now
Read now
Michele Ghidini, Alice Indini, Olga Nigro, Simona Polito, Erika Rijavec, Fausto Petrelli & Gianluca Tomasello. (2021) Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opinion on Pharmacotherapy 22:7, pages 857-865.
Read now
Read now
Kensuke Matsuda, Jo Taisuke, Masashi Miyauchi, Kazuhiro Toyama, Kumi Nakazaki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga & Mineo Kurokawa. (2020) Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses. Leukemia & Lymphoma 61:10, pages 2435-2441.
Read now
Read now
Gaetan Catala, Jeroen Mebis, Guy Jerusalem, Didier Verhoeven, Ahmad Awada, Alain Bols, Luc Somers, Anke Van Den Broeck, Francois P Duhoux & Jean-Pascal Machiels. (2020) Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clinica Belgica 75:2, pages 128-135.
Read now
Read now
John Edelsberg, Derek Weycker, Mark Bensink, Charles Bowers & Gary H. Lyman. (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion 36:3, pages 483-495.
Read now
Read now
Ali McBride, Andriy Krendyukov, Nicola Mathieson, Kim Campbell, Sanjeev Balu, Maja Natek, Karen MacDonald & Ivo Abraham. (2020) Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. Journal of Medical Economics 23:1, pages 28-36.
Read now
Read now
Derek Weycker, Mark Bensink, Alexander Lonshteyn, Robin Doroff & David Chandler. (2019) Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current Medical Research and Opinion 35:6, pages 1073-1080.
Read now
Read now
Chungam Choi, Byung Won Yoo, Choon Ok Kim, Taegon Hong, Byung Hak Jin, Kwang-Seok Seo, Ja Yun Jang & Min Soo Park. (2018) Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Drug Design, Development and Therapy 12, pages 2381-2387.
Read now
Read now
J. Mark Stephens, Mark Bensink, Charles Bowers & Christopher S. Hollenbeak. (2018) Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis. Current Medical Research and Opinion 34:8, pages 1351-1360.
Read now
Read now
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham & Sanjeev Balu. (2018) Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of Medical Economics 21:6, pages 606-609.
Read now
Read now
Mark Bensink, Christine Edwards, Charles Bowers & Jon Campbell. (2018) Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93. Journal of Medical Economics 21:6, pages 603-605.
Read now
Read now
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham & Sanjeev Balu. (2017) Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of Medical Economics 20:10, pages 1083-1093.
Read now
Read now
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H. Lyman, Spiros Tzivelekis, Guillermo Villa & Milton C. Weinstein. (2017) Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 39-52.
Read now
Read now
Matteo Lambertini, Arlindo R Ferreira, Lucia Del Mastro, Romano Danesi & Paolo Pronzato. (2015) Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert Opinion on Biological Therapy 15:12, pages 1799-1817.
Read now
Read now
Margherita Ratti & Gianluca Tomasello. (2015) Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Review of Clinical Pharmacology 8:1, pages 15-24.
Read now
Read now
Pierre Rofail, Mariam Tadros, Riham Ywakim, Mina Tadrous, Allison Krug & Leon E Cosler. (2012) Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 699-709.
Read now
Read now
Nicola Silvestris, Marzia Del Re, Amalia Azzariti, Evaristo Maiello, Lucia Lombardi, Saverio Cinieri, Attilio Guarini, Anna Elisabetta Brunetti, Sabina Delcuratolo, Fernando De Vita, Salvatore Pisconti, Romano Danesi & Giuseppe Colucci. (2012) Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opinion on Therapeutic Targets 16:sup2, pages S111-S117.
Read now
Read now
Emmanouil Saloustros, Kostas Tryfonidis & Vassilis Georgoulias. (2011) Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opinion on Pharmacotherapy 12:6, pages 851-863.
Read now
Read now
Pasquale Niscola, Andrea Tendas, Laura Scaramucci, Marco Giovaninni, Luca Cupelli, Vitaliana De Sanctis, Gregorio Antonio Brunetti, Francesco Bondanini, Roberto Palumbo, Michela Lamanda, Roberta Battistini, Claudio Cartoni, Claudio Romani & Edoardo Arcuri. (2011) Pain in malignant hematology. Expert Review of Hematology 4:1, pages 81-93.
Read now
Read now
Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler & Manja Kamprad. (2009) Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. Biologics: Targets and Therapy 3, pages 27-37.
Read now
Read now
Gary Lyman, Anjana Lalla, Richard Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 25:2, pages 401-411.
Read now
Read now
Mariko Morishita & Robert C Leonard. (2008) Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy. Expert Opinion on Biological Therapy 8:7, pages 993-1001.
Read now
Read now
Articles from other publishers (106)
Y.-E. Claessens & O. Peyrony. (2023) Neutropenia febbrile in Pronto Soccorso. EMC - Urgenze 27:2, pages 1-16.
Crossref
Crossref
Azucena Aldaz, Paula Schaiquevich & José Manuel Aramendía. (2022) A pharmacometrics model to define docetaxel target in early breast cancer. British Journal of Clinical Pharmacology 89:2, pages 727-736.
Crossref
Crossref
Matthew D. Kerr, David A. McBride, Wade T. Johnson, Arun K. Chumber, Alexander J. Najibi, Bo Ri Seo, Alexander G. Stafford, David T. Scadden, David J. Mooney & Nisarg J. Shah. (2022) Immune‐responsive biodegradable scaffolds for enhancing neutrophil regeneration. Bioengineering & Translational Medicine 8:1.
Crossref
Crossref
Girma Tekle Gebremariam, Atalay Mulu Fentie, Kebede Beyene, Beate Sander & Gebremedhin Beedemariam Gebretekle. (2022) Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. BMC Health Services Research 22:1.
Crossref
Crossref
Vincenzo Adamo, Lorenzo Antonuzzo, Marco Danova, Michelino De Laurentiis, Paolo Marchetti, Carmine Pinto & Giovanni Rosti. (2022) Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement. Supportive Care in Cancer 30:12, pages 9877-9888.
Crossref
Crossref
Hartmut Link. (2022) G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei KrebserkrankungG-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer. best practice onkologie 17:6, pages 298-314.
Crossref
Crossref
Hartmut Link. (2022) G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei KrebserkrankungG-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer. Der Urologe 61:5, pages 537-551.
Crossref
Crossref
Shruti Rastogi, Vivekanandan Kalaiselvan, Yousef A. Bin Jardan, Saima Zameer & Maryam Sarwat. (2022) Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database. Biology 11:2, pages 340.
Crossref
Crossref
Yuka Morita, Yusuke Kanemasa, Yuki Sasaki, An Ohigashi, Taichi Tamura, Shohei Nakamura, Yu Yagi, Akihiko Kageyama, Yasushi Omuro & Tatsu Shimoyama. (2022) Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. Medicine 101:10, pages e29028.
Crossref
Crossref
Yoshitaka Saito, Yoh Takekuma, Masaki Kobayashi, Tatsuhiko Sakamoto, Hiroko Yamashita & Mitsuru Sugawara. (2021) Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Supportive Care in Cancer 29:12, pages 8059-8067.
Crossref
Crossref
Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru & Maryam Sarwat. (2021) Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis. Biology 10:10, pages 1069.
Crossref
Crossref
Patrick R Tilleul, Barry S Rodgers-Gray & James O Edwards. (2020) Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator. Journal of Oncology Pharmacy Practice 27:7, pages 1604-1615.
Crossref
Crossref
Axel S. Merseburger, Götz Geiges, Jörg Klier, Martin Wiesholzer & Petra Pichler. (2021) Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting. Frontiers in Oncology 11.
Crossref
Crossref
Hrishikesh M. Mehta & Seth J. Corey. (2021) G-CSF, the guardian of granulopoiesis. Seminars in Immunology 54, pages 101515.
Crossref
Crossref
Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, Natalya N. Glonina, Natalya V. Fadeeva, Tatyana A. Sannikova, Irina S. Lyalina, Tatyana V. Shelekhova, Dmitrij G. Sherstnev, Sergey V. Voloshin, Vladislav O. Sarzhevskii, Alina A. Hofman, Damir G. Ichshanov & Irina V. Poddubnaya. (2021) Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy. Journal of Modern Oncology 22:4, pages 77-84.
Crossref
Crossref
Marie Joelle Jabagi, Norbert Vey, Anthony Goncalves, Thien Le Tri, Mahmoud Zureik & Rosemary Dray‐spira. (2020)
Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and
G‐CSF
support: A nationwide population‐based cohort
. International Journal of Cancer 148:2, pages 375-384.
Crossref
Crossref
Michael ShumanLori MossAdam Dilich. (2021) Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia. FOCUS 19:1, pages 66-70.
Crossref
Crossref
Pietro Lapidari, Ines Vaz-Luis & Antonio Di Meglio. (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Critical Reviews in Oncology/Hematology 157, pages 103193.
Crossref
Crossref
Pauline Macaire, Justine Paris, Julie Vincent, François Ghiringhelli, Leïla Bengrine‐Lefevre & Antonin Schmitt. (2020) Impact of granulocyte colony‐stimulating factor on FOLFIRINOX‐induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. British Journal of Clinical Pharmacology 86:12, pages 2473-2485.
Crossref
Crossref
Mahsa Mohseni, Morteza Arab-Zozani, Ayat Ahmadi, Babak Salimi & Ali Akbari Sari. (2020) Meta-analysis of Pegfilgrastim over Filgrastim in the Treatment of Chemotherapy-induced Neutropenia. Annals of Cancer Research and Therapy 28:2, pages 71-80.
Crossref
Crossref
Elizabeth Mclean. (2020) Acute Bone Pain: An Analysis of Symptom Management Interventions After Administration of Granulocyte–Colony-Stimulating Factors for Myelosuppression. Clinical Journal of Oncology Nursing 24:2, pages 165-169.
Crossref
Crossref
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink & Gary H. Lyman. (2019) Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC Cancer 19:1.
Crossref
Crossref
Yong Wang, Lin Chen, Fen Liu, Ning Zhao, Liyao Xu, Biqi Fu & Yong Li. (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. Scientific Reports 9:1.
Crossref
Crossref
Haruko Takuwa, Wakako Tsuji, Tomoyuki Goto, Takashi Otsuji & Fumiaki Yotsumoto. (2019) Pegfilgrastim‑induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report. Molecular and Clinical Oncology.
Crossref
Crossref
Xinguang Wang, Yingjian He, Tianfeng Wang, Yuntao Xie, Jinfeng Li, Tao Ouyang & Zhaoqing Fan. (2019) Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. Supportive Care in Cancer 27:8, pages 3019-3025.
Crossref
Crossref
Tatsuo Kataoka, Hiroshi Sakurashita, Takanori Taogoshi, Ryo Nishigakiuchi, Tetsuya Murase, Satoru Izumitani, Yasuyuki Saeki & Hiroaki Matsuo. (2019) Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy. YAKUGAKU ZASSHI 139:4, pages 629-633.
Crossref
Crossref
Andrew S. Guinigundo, Cathy L. Maxwell, Linda Vanni, Phuong Khanh Morrow, Maureen Reiner, Alex Shih, Zandra Klippel & Elizabeth Blanchard. (2018) A Randomized, Single-Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim. Pain Management Nursing 19:6, pages 693-706.
Crossref
Crossref
T Christopher Bond, Erika Szabo, Susan Gabriel, Jean Klastersky, Omar Tomey, Udo Mueller, Lee Schwartzberg & Boxiong Tang. (2017) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. Journal of Oncology Pharmacy Practice 24:6, pages 412-423.
Crossref
Crossref
Hamdy A. Azim, Shaimaa Lasheen & Loay Kassem. (2018) Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?. The Breast Journal 24:4, pages 459-461.
Crossref
Crossref
Elyse E. Lower, Mahmoud Charif & Meg Bartelt. (2018) Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study. Cancer Chemotherapy and Pharmacology 82:1, pages 165-170.
Crossref
Crossref
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven J. Hager, Emad N. Ibrahim, Makharadze Rostom, Gajanan Bhat, Mi Rim Choi, Guru Reddy, Karen L. Tedesco, Richy Agajanian, István Láng & Lee S. Schwartzberg. (2018) An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer. Cancer Medicine 7:5, pages 1660-1669.
Crossref
Crossref
Jeffrey J. Kirshner, Maxwell C. McDonaldIIIIII, Flavio Kruter, Andrew S. Guinigundo, Linda Vanni, Cathy L. Maxwell, Maureen Reiner, Terry E. Upchurch, Jacob Garcia & Phuong Khanh Morrow. (2017) NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Supportive Care in Cancer 26:4, pages 1323-1334.
Crossref
Crossref
Caroline C. Billingsley, David E. Cohn, Aleia K. Crim, Quan Li, David M. O’Malley & Laura J. Havrilesky. (2018) Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. Cancer Treatment and Research Communications 14, pages 21-25.
Crossref
Crossref
Matti Aapro, Ralph Boccia, Robert Leonard, Carlos Camps, Mario Campone, Sylvain Choquet, Marco Danova, John Glaspy, Iwona Hus, Hartmut Link, Thamer Sliwa, Hans Tesch & Vicente Valero. (2017) Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer 25:11, pages 3295-3304.
Crossref
Crossref
Gary H. Lyman, Kim Allcott, Jacob Garcia, Scott Stryker, Yanli Li, Maureen T. Reiner & Derek Weycker. (2017) The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Supportive Care in Cancer 25:8, pages 2619-2629.
Crossref
Crossref
Katherine Moore & Rachel Haroz. (2017) When Hydromorphone Is Not Working, Try Loratadine: An Emergency Department Case of Loratadine as Abortive Therapy for Severe Pegfilgrastim-Induced Bone Pain. The Journal of Emergency Medicine 52:2, pages e29-e31.
Crossref
Crossref
Sarah Mitchell, Xiaoyan Li, Matthew Woods, Jacob Garcia, Kerri Hebard-Massey, Rich Barron & Miny Samuel. (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. Journal of Oncology Pharmacy Practice 22:5, pages 702-716.
Crossref
Crossref
F. Scotté, S. Morin, A. Saadi & C. Brahmi. (2016) Toxicités hématologiques et digestives en cancérologie thoracique. Revue des Maladies Respiratoires Actualités 8:5, pages 478-488.
Crossref
Crossref
Pamala A Pawloski, Mitch Larsen, Assel Thoresen & Monique D Giordana. (2015) Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients. Journal of Oncology Pharmacy Practice 22:3, pages 423-429.
Crossref
Crossref
Radosław Mądry, Lidia Popławska, Ferdinand Haslbauer, Martin Šafanda, Doru Ghizdavescu, Jana Benkovicova, Tibor Csőszi, Georgi Mihaylov, Daniela Niepel, Christine Jaeger, Iveta Frkanova, Alina Macovei & Christine Staudigl. (2016) Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wiener klinische Wochenschrift 128:7-8, pages 238-247.
Crossref
Crossref
I. M. Bondarenko, P. Bias & A. Buchner. (2015) Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Supportive Care in Cancer 24:1, pages 267-273.
Crossref
Crossref
Li Wang, Onur Baser, Lucie Kutikova, John H. Page & Richard Barron. (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer 23:11, pages 3131-3140.
Crossref
Crossref
Edgar Petru, Christian F. Singer, Stephan Polterauer, Arik Galid, Christian Schauer, Johann Klocker, Michael Seifert, Alexander Reinthaller, Christoph Benedicic, Michael Hubalek, Lukas Hefler, Christian Marth, Tonja Scholl-Firon, Gerhard Bogner & Alain-Gustave Zeimet. (2015) Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementProphylaxe mit langwirksamen Granulozyten-Kolonie-stimulierenden Faktoren (G-CSF) bei gynäkologischen Malignomen. Wiener Medizinische Wochenschrift 165:19-20, pages 387-394.
Crossref
Crossref
. (2015) Référentiels inter régionaux en Soins Oncologiques de SupportSymptômes articulaires liés aux traitements du cancer. Oncologie 17:10, pages 411-433.
Crossref
Crossref
Georgia Kourlaba, Meletios A. Dimopoulos, Dimitrios Pectasides, Dimosthenis V. Skarlos, Helen Gogas, George Pentheroudakis, Angelos Koutras, George Fountzilas & Nikos Maniadakis. (2014) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Supportive Care in Cancer 23:7, pages 2045-2051.
Crossref
Crossref
Kim G. Hankey, Ann M. Farese, Erica C. Blaauw, Allison M. Gibbs, Cassandra P. Smith, Barry P. Katz, Yan Tong, Karl L. Prado & Thomas J. MacVittie. (2015) Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. Radiation Research 183:6, pages 643-655.
Crossref
Crossref
Valentina Bozzoli, Maria C. Tisi, Elena Maiolo, Eleonora Alma, Silvia Bellesi, Francesco D'Alo’, Maria T. Voso, Giuseppe Leone & Stefan Hohaus. (2015)
Four doses of unpegylated
versus
one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma
. British Journal of Haematology 169:6, pages 787-794.
Crossref
Crossref
Mova Leung, Joy Florendo, Jessica Kano, Tiffany Marr-Del Monte, Brian Higgins, Robert Myers, Trishala Menon & Glenn Jones. (2014) A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer. Supportive Care in Cancer 23:6, pages 1669-1677.
Crossref
Crossref
Esther K. Lee, William W. L. Wong, Maureen E. Trudeau & Kelvin K. W. Chan. (2015) Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Research and Treatment 150:1, pages 169-180.
Crossref
Crossref
Alena M. Pfeil, Kim Allcott, Ruth Pettengell, Gunter von Minckwitz, Matthias Schwenkglenks & Zsolt Szabo. (2014) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Supportive Care in Cancer 23:2, pages 525-545.
Crossref
Crossref
Anton Buchner, Reiner Elsässer & Peter Bias. (2014) A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Research and Treatment 148:1, pages 107-116.
Crossref
Crossref
Rickey C. Miller & Alison Steinbach. (2014) Growth Factor Use in Medication-Induced Hematologic Toxicity. Journal of Pharmacy Practice 27:5, pages 453-460.
Crossref
Crossref
C. Andersen, M. Rørth, B. Ejlertsen & L. Adamsen. (2014)
Exercise despite pain
- breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention
. European Journal of Cancer Care 23:5, pages 653-667.
Crossref
Crossref
Ellen Catuiza Mullen. (2014) Pegfilgrastim-Induced Pain in Patients With Lymphoma. Oncology Nursing Forum 41:2, pages 212-214.
Crossref
Crossref
Matteo Lambertini, Lucia Del Mastro, Andrea Bellodi & Paolo Pronzato. (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Critical Reviews in Oncology/Hematology 89:1, pages 112-128.
Crossref
Crossref
Y.-E. Claessens, E. Trabattoni, S. André, H. Clément & C. Andréotti. (2013) Neutropenia febbrile e Pronto Soccorso. EMC - Urgenze 17:4, pages 1-12.
Crossref
Crossref
S. Zeynalova, M. Ziepert, M. Scholz, S. Schirm, C. Zwick, M. Pfreundschuh & M. Loeffler. (2013) Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Annals of Hematology 92:12, pages 1641-1652.
Crossref
Crossref
L. Balducci, D. Goetz-Parten & M.A. Steinman. (2013) Polypharmacy and the management of the older cancer patient. Annals of Oncology 24, pages vii36-vii40.
Crossref
Crossref
L. Jolis, F. Carabantes, S. Pernas, B. Cantos, A. López, P. Torres, C. Funes, D. Caballero, P. Benedit & A. Salar. (2013) Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. European Journal of Cancer Care 22:4, pages 513-521.
Crossref
Crossref
D. Almenar Cubells, C. Bosch Roig, E. Jiménez Orozco, R. Álvarez, J.M. Cuervo, N. Díaz Fernández, A.B. Sánchez Heras, A. Galán Brotons, V. Giner Marco & M. Codes M. De Villena. (2013) Effectiveness of daily versus non‐daily granulocyte colony‐stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. European Journal of Cancer Care 22:3, pages 400-412.
Crossref
Crossref
Y.-E. Claessens, E. Trabattoni, S. André, H. Clément & C. Andréotti. (2013) Neutropénie fébrile et urgences. EMC - Médecine d 'urgence 8:1, pages 1-12.
Crossref
Crossref
James C. Wade. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
1165
1191
.
Jerzy Wordliczek & Renata Zajaczkowska. 2013. Cancer Pain. Cancer Pain
47
70
.
Markus Scholz, Sibylle Schirm, Marcus Wetzler, Christoph Engel & Markus Loeffler. (2012) Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. Theoretical Biology and Medical Modelling 9:1.
Crossref
Crossref
José Muñoz Langa, Pere Gascón & Javier de Castro. (2012) SEOM clinical guidelines for myeloid growth factors. Clinical and Translational Oncology 14:7, pages 491-498.
Crossref
Crossref
Bradford R. Hirsch & Gary H. Lyman. (2012) Pharmacoeconomics of the Myeloid Growth Factors. PharmacoEconomics 30:6, pages 497-511.
Crossref
Crossref
Matti Aapro, Paul Cornes & Ivo Abraham. (2011) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. Journal of Oncology Pharmacy Practice 18:2, pages 171-179.
Crossref
Crossref
Prahlad Ho, Peter Sherman & Andrew Grigg. (2012) Intermittent granulocyte colony‐stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. European Journal of Haematology 88:5, pages 416-421.
Crossref
Crossref
Bernd C. Kieseier & Peter A. Calabresi. (2012) PEGylation of Interferon-β-1a. CNS Drugs 26:3, pages 205-214.
Crossref
Crossref
Anna Urbańczyk & Jan Styczyński. (2012) Analiza porównawcza przebiegu neutropenii po chemioterapii i zastosowaniu czynnika wzrostu kolonii granulocytarnych lub jego formy pegylowanej. Pediatria Polska 87:2, pages 165-168.
Crossref
Crossref
Tara L. Arvedson & Graham Molineux. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
151
168
.
Katy L Cooper, Jason Madan, Sophie Whyte, Matt D Stevenson & Ron L Akehurst. (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:1.
Crossref
Crossref
Andrea V. Page & W. Conrad Liles. (2011) Colony-Stimulating Factors in the Prevention and Management of Infectious Diseases. Infectious Disease Clinics of North America 25:4, pages 803-817.
Crossref
Crossref
Jason Madan, Matt D. Stevenson, Katy L. Cooper, A.E. Ades, Sophie Whyte & Ron Akehurst. (2011) Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable?. Value in Health 14:6, pages 953-960.
Crossref
Crossref
Fiona L DAY, James M BULL, Janine M LOMBARD & John F STEWART. (2011) Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution's experience. Asia-Pacific Journal of Clinical Oncology 7:2, pages 146-153.
Crossref
Crossref
Bassam Estfan. (2011) Essential Drugs in Supportive Care. Seminars in Oncology 38:3, pages 413-423.
Crossref
Crossref
Jean Klastersky & Ahmad Awada. (2011) Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. Critical Reviews in Oncology/Hematology 78:1, pages 17-23.
Crossref
Crossref
Yoshihiro Yakushijin, Hisaharu Shikata, Ikue Takaoka, Tamami Horikawa, Kazuhito Takeuchi, Jun Yamanouchi, Taichi Azuma, Hiroshi Narumi, Takaaki Hato & Masaki Yasukawa. (2010) Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. International Journal of Clinical Oncology 16:2, pages 118-124.
Crossref
Crossref
Alexandre CHAN, Xue Zhen LENG, Joen YL CHIANG, Miriam TAO, Richard QUEK, Kevin TAY & Soon Thye LIM. (2011) Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia-Pacific Journal of Clinical Oncology 7:1, pages 75-81.
Crossref
Crossref
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young & John R. Wingard. (2011) Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, pages 427-431.
Crossref
Crossref
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber & C. Zielinski. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 47:1, pages 8-32.
Crossref
Crossref
Jean-François Morère, Françoise Mornex & Denis SoulièresH. Chaaba & S. Piperno-Neumann. 2011. Thérapeutique du cancer. Thérapeutique du cancer
893
908
.
Gary H. Lyman & Nicole M. Kuderer. 2011. Practical Geriatric Oncology. Practical Geriatric Oncology
323
337
.
Stephanie A. Gregory, Lee S. Schwartzberg, May Mo, Jorge Sierra & Charles Vogel. (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis. Community Oncology 7:7, pages 297-308.
Crossref
Crossref
Matti Aapro, Matthias Schwenkglenks, Gary H. Lyman, Antonio Lopez Pousa, Susan Lawrinson, Tomas Skacel, Pamela Bacon & Gunter von Minckwitz. (2010) Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology/Hematology 74:3, pages 203-210.
Crossref
Crossref
Matti Aapro, Jeffrey Crawford & Didier Kamioner. (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. Supportive Care in Cancer 18:5, pages 529-541.
Crossref
Crossref
Elizabeth Fox, Brigitte C. Widemann, Douglas S. Hawkins, Nalini Jayaprakash, Ramzi Dagher, Alberta A. Aikin, Donna Bernstein, Lauren Long, Crystal Mackall, Lee Helman, Seth M. Steinberg & Frank M. Balis. (2009) Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas. Clinical Cancer Research 15:23, pages 7361-7367.
Crossref
Crossref
M. Scholz, C. Engel, D. Apt, S. L. Sankar, E. Goldstein & M. Loeffler. (2009) Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. Cell Proliferation 42:6, pages 823-837.
Crossref
Crossref
M. Scholz, M. Ackermann, C. Engel, F. Emmrich, M. Loeffler & M. Kamprad. (2009) A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Proliferation 42:6, pages 813-822.
Crossref
Crossref
John R. Wingard & Mohamed Elmongy. (2009) Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Critical Reviews in Oncology/Hematology 72:2, pages 144-154.
Crossref
Crossref
Zhimei Liu, Quan V. Doan, Jennifer Malin & Robert Leonar. (2012) The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Applied Health Economics and Health Policy 7:3, pages 193-205.
Crossref
Crossref
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, Dolores Caballero, Bertrand Coiffier, Michael Pfreundschuh, Marek Trneny & Jan Walewski. (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation 29:8, pages 491-513.
Crossref
Crossref
Jean Klastersky, Ahmad Awada, Michel Aoun & Marianne Paesmans. (2009) Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?. Current Opinion in Oncology 21:4, pages 297-302.
Crossref
Crossref
William Renwick, Ruth Pettengell & Michael Green. (2009) Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy. BioDrugs 23:3, pages 175-186.
Crossref
Crossref
Amy P. Abernethy, Sally Y. Barbour, Hope Uronis, S. Yousuf Zafar, April Coan, Krista Rowe, Mary Ruth Pupa, Jane L. Wheeler & James E. Herndon II. (2008) Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Supportive Care in Cancer 17:6, pages 735-744.
Crossref
Crossref
Derek Weycker, Jennifer Malin, John Kim, Rich Barron, John Edelsberg, Alex Kartashov & Gerry Oster. (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clinical Therapeutics 31:5, pages 1069-1081.
Crossref
Crossref
Gary H. Lyman, Anjana Lalla, Richard L. Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics 31:5, pages 1092-1104.
Crossref
Crossref
Marco Danova, Silvia Chiroli, Giovanni Rosti & Quan V Doan. (2018) Cost-Effectiveness of Pegfilgrastim versus Six Days of Filgrastim for Preventing Febrile Neutropenia in Breast Cancer Patients. Tumori Journal 95:2, pages 219-226.
Crossref
Crossref
Jenny M. Whitworth, Kellie S. Matthews, Kimberly A. Shipman, T. Michael Numnum, James E. Kendrick, Larry C. Kilgore & J. Michael StraughnJr.Jr.. (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecologic Oncology 112:3, pages 601-604.
Crossref
Crossref
Christine Herbst, Frauke Naumann, Eva-Brigitta Kruse, Ina Monsef, Julia Bohlius, Holger Schulz & Andreas Engert. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Emilie Milano-Bausset, Jean Gaudart, Angelique Rome, Carole Coze, Jean Claude Gentet, Laetitia Padovani, Bruno Lacarelle & Nicolas André. (2009) Retrospective comparison of neutropenia in children with ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clinical Therapeutics 31, pages 2388-2395.
Crossref
Crossref
Julia Bohlius, Christine Herbst, Marcel Reiser, Guido Schwarzer & Andreas Engert. (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews.
Crossref
Crossref
S Dallorso, M Berger, I Caviglia, T Emanueli, M Faraci, L Scarso, F Fagioli & R Haupt. (2008) Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. Bone Marrow Transplantation 42:8, pages 507-513.
Crossref
Crossref
José Ignacio Mayordomo Cámara, Antonio López Pousa, Emmanuel Giménez García, Xavier Badia Llach, Núria Lara Surinyach, Francesc Sorio Vilela, Zhimei Liu & Raúl Arocho. (2013) Evaluación económica del uso de pegfilgrastim frente a filgrastim en profilaxis primaria en pacientes con cáncer de mama con riesgo de padecer neutropenia febril en España. PharmacoEconomics Spanish Research Articles 5:3, pages 71-81.
Crossref
Crossref
Jeffrey Crawford. 2008. Cancer Supportive Care: Advances in Therapeutic Strategies. Cancer Supportive Care: Advances in Therapeutic Strategies
1
29
.
Joyce A. O'Shaughnessy. (2007) Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer. Clinical Breast Cancer 8, pages S11-S21.
Crossref
Crossref